EUVIMEDEUVIMED entdecken
Open Access

Genetically engineered human cell–based microrobots for selective cancer cell death

Nihal Olcay Dogan iD, Eylül Suadiye iD, Julia Unangst, Cem Balda Dayan iD, Gunther Richter iD, Ahmet Cingöz iD, Tugba Bagci-Onder iD, Metin Sitti iD

Science Advances · 2026

DOI: 10.1126/sciadv.aea9831 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Nihal Olcay Dogan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Physical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569 Stuttgart, Germany. Hauptthemen laut MEDLINE: TNF-Related Apoptosis-Inducing Ligand, Genetic Engineering, Neoplasms, Robotics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Max-Planck-Gesellschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medical microrobots have strong potential for targeted therapeutic delivery; however, current systems achieve only physical targeting, and once at the target site, they are unable to distinguish healthy cells from cancerous ones because of the lack of biological selectivity. Here, we present a biohybrid microrobot system that combines magnetic targeting with biological selectivity. The microrobots are derived from human embryonic kidney cells genetically engineered to produce tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a molecule that induces cancer cell death in multiple tumor types without damaging healthy cells. Engineered cells are then conjugated to biocompatible magnetic Janus particles—silica beads half-coated with FePt nanofilms—to enable external magnetic control. With magnetic fields, the microrobots accumulate around the tumor spheroids and continuously release TRAIL for several days, leading to selective cancer cell death while avoiding damage to healthy cells. This study combines microrobotics with genetically engineered cell therapies to achieve a targeted, prolonged, and cancer-selective therapeutic delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TNF-Related Apoptosis-Inducing LigandGenetic EngineeringNeoplasmsRoboticsHumansCell DeathHEK293 CellsCell Line, TumorDrug Delivery SystemsCell Engineering

Substanzen

TNF-Related Apoptosis-Inducing Ligand

Autor:innen und Institutionen

  • Physical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569 Stuttgart, Germany.
  • Institute for Biomedical Engineering, ETH Zurich, 8092 Zurich, Switzerland.
  • Materials Central Scientific Facility, Max Planck Institute for Intelligent Systems, 70569 Stuttgart, Germany.
  • Robotic Materials Department, Max Planck Institute for Intelligent Systems, 70569 Stuttgart, Germany.
  • School of Medicine, Koç University, 34450 Istanbul, Turkey.
  • Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, 34820 Istanbul, Turkey.

ORCID-Profile: Nihal Olcay Dogan, Eylül Suadiye, Cem Balda Dayan, Gunther Richter, Ahmet Cingöz, Tugba Bagci-Onder, Metin Sitti

Förderung

  • Max-Planck-Gesellschaft

Zitieren

APA

Dogan, N. O., Suadiye, E., Unangst, J., Dayan, C. B., Richter, G., Cingöz, A., Bagci-Onder, T., & Sitti, M. (2026). Genetically engineered human cell–based microrobots for selective cancer cell death. Science Advances. https://doi.org/10.1126/sciadv.aea9831

Vancouver

Dogan NO, Suadiye E, Unangst J, Dayan CB, Richter G, Cingöz A, et al. Genetically engineered human cell–based microrobots for selective cancer cell death. Science Advances. 2026. doi:10.1126/sciadv.aea9831

BibTeX
@article{Dogan2026,
  author = {Dogan, Nihal Olcay and Suadiye, Eylül and Unangst, Julia and Dayan, Cem Balda and Richter, Gunther and Cingöz, Ahmet and Bagci-Onder, Tugba and Sitti, Metin},
  title = {Genetically engineered human cell–based microrobots for selective cancer cell death},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aea9831}
}
Kostenlos starten →